Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioVentrix: Reshaping Heart Failure

Executive Summary

BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.

You may also be interested in...



BioVentrix Continues Battle To Remodel Post-Attack Hearts

Following reimbursement approval in Germany, BioVentrix is making headway in long-neglected post-heart attack treatments.

Start-Up Spotlight: BioVentrix Expects Revivent TC Heart Failure Device To Succeed Where Others Failed

Two-year data from a European trial showed BioVentrix’s Revivent TC system significantly reduces left-ventricular volume and improves left-ventricular function in patients with heart failure following a myocardial infarction. The company expects to complete a US pivotal trial of the device in 2021 and launch the device in the US with funding from a planned initial public offering.

BioVentrix Advances Its Revivent-TC Ventricular Enhancement Technology For Heart Failure

BioVentrix Inc. has its sights set on US market approval for its hybrid transthoracic-endovascular Revivent-TC system, a unique device that enables a minimally invasive approach to treating patients who develop ischemic heart failure following a heart attack.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT035696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel